Feb 19: Bavaguthu Raghuram Shetty was once a typical billionaire with a taste for the high-life.
He splurged on a private jet, vintage cars and two entire floors of the Burj Khalifa, the world’s tallest skyscraper. His website shows him hobnobbing with politicians, Bill Gates and Bollywood royalty.
“The thrill of speed and freedom makes me love cars,” Shetty, 77, told local reporters last year.
Shetty had more than enough money -- at least on paper -- to afford such a lifestyle from companies he helped found, including hospital operator NMC Health Plc and financial services firm Finablr Plc. On Dec. 10, his stakes in the public companies were valued at $2.4 billion, making up the bulk of a fortune spanning education, hospitality and one of the world’s oldest tea companies.
Then, a week later, Carson Block came along.
Block’s investment firm, Muddy Waters, issued a report criticizing NMC’s accounts and disclosing a short position. Since then, Muddy Waters’s scrutiny has snowballed into a troubling scenario for Shetty that sheds light on his complex share arrangements and casts doubts about his net worth. His holdings in Finablr and NMC are worth $885 million, but Shetty’s fortune may now be just a fraction of that, depending on the size of his borrowings.
Filings this month show that Shetty pledged a quarter of his NMC stake against loans with First Abu Dhabi Bank and Zurich-based Falcon Private Bank. Two other shareholders may own half of his reported stake. Another lender -- Al Salam Bank Bahrain -- has already sold some of those shares to enforce security over a loan for Shetty, and NMC said Tuesday that First Abu Dhabi Bank sold another chunk earlier this month.
The situation “seems to have gone beyond some of the issues that Muddy Waters focused on initially,“ said Gavin Launder, a fund manager at Legal & General Investment Management, who owned shares in NMC until October. “The increased scrutiny has unearthed other issues.”
Law firm Herbert Smith Freehills has launched a review of Shetty’s holdings at his request, a spokesperson for the Indian-born businessman said, declining to comment further until the analysis is completed. Shetty resigned Sunday as NMC’s chairman.
In its Dec. 17 report on NMC, Muddy Waters hinted at potential overpayment for assets, inflated cash balances and understated debt. Shares of the United Arab Emirates’ biggest private health-care provider have since plunged 67%, and the firm is now the focus of takeover speculation. The sell-off also spread to Finablr, whose stock has tumbled 64% in that span.
NMC has disputed Muddy Waters’s claims, and the company hired former FBI Director Louis Freeh to conduct an independent review of the short seller’s allegations. Meanwhile, local regulators “are making inquiries with the relevant parties,” a spokesperson for the U.K.’s Financial Conduct Authority said.
Shetty is hardly the only ultra-wealthy person to leverage his assets. Elon Musk has used his shares in Tesla Inc. to obtain personal loans, while Oracle Corp. Chairman Larry Ellison has put up millions of the company’s shares to fund a lavish lifestyle that includes trophy properties, America’s Cup teams and the Indian Wells tennis facility in California.
But such deals can also sour, as demonstrated by Shetty’s lenders selling shares his investment firm pledged. He and his advisers are investigating details of the sales as part of their legal review, according to filings.
To complicate matters, Shetty pledged another batch of NMC stock in 2018 as part of a so-called equity collar arrangement with Goldman Sachs Group Inc. that uses options to limit the impact from share moves. Last month, he also pledged most of his stake in Finablr to refinance a loan from the company’s takeover of foreign-exchange firm Travelex for about $1.2 billion.
BRS Ventures Investment, the UAE-based holding company for most of Shetty’s assets, doesn’t report consolidated financials, preventing a complete analysis of his net worth. His other assets include a catering company, a waste-management firm and pharmaceutical business Neopharma, which four months ago was in the early stages of planning for an initial public offering.
Block, 43, earned his reputation as a short seller a decade ago through targeting U.S.-listed Chinese companies that he claimed were frauds. More recently, his San Francisco-based firm focused on British litigation-finance firm Burford Capital Ltd. and Japanese biotech stock PeptiDream Inc. Short sellers seek to benefit from a decline in a company’s share price.
Shetty founded NMC in 1975 after moving to Abu Dhabi from his native India. He created Finablr two years ago to consolidate his financial brands before listing it on the London Stock Exchange in 2019.
Block said he didn’t anticipate NMC’s shareholding drama.
“I wouldn’t have been able to predict that we’d get these bizarre disclosures about unclear share ownership coming out of the company,” he said in a Feb. 13 phone interview. “This has been obviously a more dramatic unraveling than we usually see.”
Comments
Trials of drug dexamethasone in Covid-19 cases have brought success in saving lives , claim Oxford University scientists on 16 June 2020.
According to news reports on 16 June , 2020 , Oxford University Scientists have conducted trials on anti-inflammatory steroid Dexamethasone in Covid-19 cases. Results released by the Oxford University on 16 June 2020 say that the low-cost and easily available drug saves the people seriously infected by Coronavirus , cuts the death risk by a third for those on ventilators and by a fifth for those on oxygen. The commentary on the drug reads like this :-
“ This is a tremendous news today from the recovery trial showing that dexamethasone is the first drug to reduce mortality from Covid-19. It is particularly exciting as this is an inexpensive widely available medicine. This is a ground breaking development in our fight against the disease and the speed at which researchers have progressed finding an effective treatment , is truly remarkable. It shows importance of doing high quality clinical trials and basing decisions as the results of those trials”.
Covid-19 has taken into its grip the entire world during first half of the year 2020 , infecting lacs and killing also lacs of its patients. In the absence of an effective drug or vaccine , people had no choice other than to look up to the heavens or scientists to come with some cure. And the drug described here is the first one to respond to the prayer of the global community , it seems. As regards a vaccine , only few are claiming that it can come by the end of the present year 2020. Rather , some are of the view that it may take a larger part of the year 2021 and could even go to mid-2022. Whatever that scenario about prospect of arrival of vaccine to treat Covid-19 may be , the news that was broken on 16 June 2020 by the Oxford University scientists in relation to drug dexamethasone would have sent a wave of strength and hope among people world-wide. And this Vedic astrology writer was spirited for another reason as well - a prediction of when some relief by way of drug to fight Covid-19 may appear , having come accurate in the claim announced by Oxford University on 16 June 2020. This writer had , based on interpretation and application of Vedic astrology , contributed in early April , 2020 an opinion piece - “ Some searchlight on way out of Covid-19 presently tormenting mankind” - to a number of newspapers. It was also contributed on 11 April , 2020 using the ‘ comments’ column of article -‘ Heard Charles took Ayurveda treatment-based Ayush drugs for Covid-19’ - at theprint.in/india/looking-at-evidence-based-ayush-medicines-to-treat-covid-19-minister-shripad-naik/393407/. The text in the opinion piece related to the claim of success announced by Oxford University scientists on 16 June , 2020 , reads like this :-
“ So reading in between the lines , it can be said that some effective drug or remedy can arrive by mid or towards the last week of June 2020 to provide some relief during July to September 2020 , to some good extent”.
The point this writer wants to share with readers world-wide is that yes , a drug envisaged in the aforesaid prediction has appeared on the horizon in the claim announcement of Oxord University scientists on 16 June , 2020.
Bio :-
Kushal kumar ,
202-GH28 , Mansarovar Apartments ,
Sector 20 , Panchkula-134116 , Haryana,
India.
Note :- This writer’s significant predictive work covering 2020 about the U.S. and Italy
Add new comment